Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:95890rdf:typepubmed:Citationlld:pubmed
pubmed-article:95890lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:95890lifeskim:mentionsumls-concept:C0023884lld:lifeskim
pubmed-article:95890lifeskim:mentionsumls-concept:C0035608lld:lifeskim
pubmed-article:95890lifeskim:mentionsumls-concept:C0032863lld:lifeskim
pubmed-article:95890lifeskim:mentionsumls-concept:C0444956lld:lifeskim
pubmed-article:95890pubmed:issue6lld:pubmed
pubmed-article:95890pubmed:dateCreated1978-8-28lld:pubmed
pubmed-article:95890pubmed:abstractTextThe possible induction of fatty liver by Rifampicin has been investigated by oral administration of two different doses (200 and 400 mg/kg/24 h) of this antibiotic for a period of 8 days to male and female Rats. The results obtained are more constant and more coherent in male than in female. It is the 400 mg/kg/24 h dose which is more effective, leading to an increase of lipids, triglycerides and cholesterol in the liver and a decrease of serum triglycerides. A dose-effect relationship may exist. These preliminary data lead us to believe that Rifampicin may inhibit the synthesis of the protein moiety of lipoproteins, such as alpha-Amanitin, which is also a RNA-polymerase inhibitor.lld:pubmed
pubmed-article:95890pubmed:languagefrelld:pubmed
pubmed-article:95890pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:95890pubmed:citationSubsetIMlld:pubmed
pubmed-article:95890pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:95890pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:95890pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:95890pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:95890pubmed:statusMEDLINElld:pubmed
pubmed-article:95890pubmed:monthFeblld:pubmed
pubmed-article:95890pubmed:issn0567-655Xlld:pubmed
pubmed-article:95890pubmed:authorpubmed-author:TruhautRRlld:pubmed
pubmed-article:95890pubmed:authorpubmed-author:WarnetJ MJMlld:pubmed
pubmed-article:95890pubmed:authorpubmed-author:ClaudeJ RJRlld:pubmed
pubmed-article:95890pubmed:authorpubmed-author:PiriouAAlld:pubmed
pubmed-article:95890pubmed:authorpubmed-author:JacquesonAAlld:pubmed
pubmed-article:95890pubmed:issnTypePrintlld:pubmed
pubmed-article:95890pubmed:day13lld:pubmed
pubmed-article:95890pubmed:volume286lld:pubmed
pubmed-article:95890pubmed:ownerNLMlld:pubmed
pubmed-article:95890pubmed:authorsCompleteYlld:pubmed
pubmed-article:95890pubmed:pagination493-7lld:pubmed
pubmed-article:95890pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:95890pubmed:meshHeadingpubmed-meshheading:95890-An...lld:pubmed
pubmed-article:95890pubmed:meshHeadingpubmed-meshheading:95890-Se...lld:pubmed
pubmed-article:95890pubmed:meshHeadingpubmed-meshheading:95890-Ch...lld:pubmed
pubmed-article:95890pubmed:meshHeadingpubmed-meshheading:95890-Ra...lld:pubmed
pubmed-article:95890pubmed:meshHeadingpubmed-meshheading:95890-Li...lld:pubmed
pubmed-article:95890pubmed:meshHeadingpubmed-meshheading:95890-Li...lld:pubmed
pubmed-article:95890pubmed:meshHeadingpubmed-meshheading:95890-Fa...lld:pubmed
pubmed-article:95890pubmed:meshHeadingpubmed-meshheading:95890-Fe...lld:pubmed
pubmed-article:95890pubmed:meshHeadingpubmed-meshheading:95890-Ma...lld:pubmed
pubmed-article:95890pubmed:meshHeadingpubmed-meshheading:95890-Tr...lld:pubmed
pubmed-article:95890pubmed:meshHeadingpubmed-meshheading:95890-Ri...lld:pubmed
pubmed-article:95890pubmed:meshHeadingpubmed-meshheading:95890-Do...lld:pubmed
pubmed-article:95890pubmed:year1978lld:pubmed
pubmed-article:95890pubmed:articleTitle[Liver steatogenic power of high doses of rifampicin in rats].lld:pubmed
pubmed-article:95890pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:95890pubmed:publicationTypeEnglish Abstractlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:95890lld:pubmed